SIGA Gains $113M Contract for Smallpox Vaccine

The oral Tpoxx medication manufactured by SIGA Technologies has been purchased by the US Department of Health and Human Services.

The arrangement, which is estimated to be worth $113 million, expands upon the prior Tpoxx procurement agreement that was made with the US HHS. The US HHS placed an order for the Tpoxx vaccine in July 2023 for around $138 million.

The orthopoxvirus, which may cause cowpox, smallpox, mpox (monkeypox), and vaccinia virus, is the target for Tpoxx. The FDA has authorised it only for the treatment of smallpox. Yet, along with smallpox, the European Medicines Agency and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) have authorised the medication to treat cowpox, mpox, and sequelae from vaccinia.

The need for mpox vaccinations surged in the wake of the 2022 pandemic. The Tpoxx and Jynneos vaccinations are still in high demand even if the number of mpox cases has decreased over the past year. This is because many nations are purchasing the vaccines to reduce the possibility of mpox outbreaks.